Adrenocorticotropic hormone: an effective “natural” biologic therapy for acute gout?
- 26 July 2020
- journal article
- review article
- Published by Springer Nature in Rheumatology International
- Vol. 40 (12) , 1941-1947
Abstract
Treatment of acute gout consists of non-steroidal anti-inflammatory drugs (NSAIDs), colchicine and steroids. However, the typical patient with gout has multiple comorbidities such as cardiovascular disease, hypertension, renal dysfunction or diabetes/metabolic syndrome that represent contraindications to these therapeutic options. The aim of this study is to review the available evidence regarding the use of ACTH as an alternative therapeutic option for acute gout and explore potential mechanisms of action. We performed an electronic search (MEDLINE, Scopus and Web of Science) using the keywords ACTH or adrenocorticotropic hormone combined with gout or crystal-induced arthritis. ACTH appears suitable for patients with many comorbidities due to its good safety profile. Clinical evidence shows that ACTH is at least as effective as classic agents. The mechanism of action of ACTH in gout is not entirely known. Robust experimental evidence points to the direction that ACTH does not act solely by triggering the release of endogenous steroids but also appears to downregulate inflammatory responses by activating melanocortin receptors on innate immune cells, such as macrophages. Moreover, indirect evidence indicates that ACTH may have an IL-1 antagonistic effect. We propose that ACTH may be an alternative therapeutic option for gout in patients with multiple comorbidities. Large-scale studies assessing the efficacy and safety of ACTH compared to classic therapeutic options are needed.Keywords
This publication has 47 references indexed in Scilit:
- Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin PeptidesInternational Journal of Inflammation, 2013
- Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensionsAnnals of the Rheumatic Diseases, 2012
- 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritisArthritis Care & Research, 2012
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care & Research, 2012
- Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cellsArthritis Research & Therapy, 2009
- Gout – what are the treatment options?Expert Opinion on Pharmacotherapy, 2009
- A Randomized Pilot Trial Comparing Methylprednisolone Plus a Cytotoxic Agent Versus Synthetic Adrenocorticotropic Hormone in Idiopathic Membranous NephropathyAmerican Journal of Kidney Diseases, 2006
- Dissection of the Anti-Inflammatory Effect of the Core and C-Terminal (KPV) α-Melanocyte-Stimulating Hormone PeptidesThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Molecular Basis of the α‐MSH/IL‐1 AntagonismAnnals of the New York Academy of Sciences, 1999
- Mechanisms of the Antiinflammatory Effects of α‐MSH: Role of Transcription Factor NF‐κB and Adhesion Molecule ExpressionAnnals of the New York Academy of Sciences, 1999